echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > A Novel Chimeric Antigen Receptor T-Cell Approach to Treat Liver Cancer

    A Novel Chimeric Antigen Receptor T-Cell Approach to Treat Liver Cancer

    • Last Update: 2022-09-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, the research team of Han Zeguang from the Institute of Systems Biomedicine, Shanghai Jiao Tong University published an article titled DLK1-directed chimeric antigen receptor T-cell therapy for hepatocellular carcinoma online in the well-known academic journal Liver International, revealing a novel targeting membrane protein DLK1.


    Chimeric antigen receptor T cells (CAR-T) immunotherapy, as a promising method of adoptive T cell therapy, has achieved remarkable results in the treatment of hematological tumors , but also brought a new dawn for the treatment of solid tumors (Figure 1)


    Figure 1.


    In this study, DLK1 is a membrane protein and has important roles in liver development and tumorigenesis


    Figure 2.


    Figure 3.


    This study provides a new CAR-T cell therapy targeting the membrane antigen DLK1, which has the potential to be further developed as a clinical immunotherapy for liver cancer


    Prof.


    Paper link: https://onlinelibrary.


    Han Zeguang

    Institute of Systems Biomedicine

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.